-Maria Scott
Wednesday 28th March 2007 |
Text too small? |
The most marked increases have been in the cost of five year loans driven by sharp rises in the five year swap. BNZ was paying 7.71% for five year funding at the end of last week compared with 7.4% a fortnight earlier. The bank's mortgage rates are all priced at above their five year averages.
Today it has withdrawn its seven-year rate.
Banks are paying more for mortgage funds because of the continued demand for housing finance and because economic indicators suggest that the official cash rate may have to rise again.
ANZ and the National Bank have announced three sets of increases to fixed rate loans since the OCR increase. The banks are now charging more than their mainstream competitors across all terms.
Over five years, for example, their rates are 8.6% compared with 8.15% from Westpac and from BNZ on its Standard and FlyBuys, ASB is charging 8.30%. ANZ's five year rate is now the same as the two-year rates charged by ASB and Westpac and by BNZ on its Standard and FlyBuys option. BNZ's Classic Unbeatable 2-year fixed rate is now at 8.42%.
However, this market is moving quickly and ANZ/National's competitors may soon follow them upwards.
Five year rates had become popular in recent weeks because they were cheaper than loans over shorter terms. But now that they are edging up towards the shorter term rates or even on a par with them, depending on the banks you compare, borrowers may feel it is risky to tie themselves in over five years.
The trend in interest rates over the last year has defied the prediction of most market watchers; that rates would have peaked by now.
It is looking increasingly attractive to avoid trying to second guess the market and hedge bets by borrowing some money over a short term and some over a longer period.
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors